Renaissance and GlaxoSmithKline Transfer Nine Products

06/05/2013

Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's branded division Prestium Pharma, include: 1. Evoclin® (clindamycin phosphate) Foam, 1% 2. Extina® (ketoconazole) Foam, 2% 3. Luxiq® (betamethasone valerate) Foam, 0.12% 4. Olux® (clobetasol propionate) Foam, 0.05% 5. Olux-E® (clobetasol propionate) Foam, 0.05% 6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment 7. Zovirax® (acyclovir) Capsules 8. Zovirax® (acyclovir) Tablets 9. Zovirax® (acyclovir) Suspension
Register

We're glad to see you're enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free